GI endoscopy and anticoagulant therapy -a multicenter obsevational study
Not Applicable
- Conditions
- Patients who are treated with anticoagulant drugs requiring endoscopic biopsy or therapeutics
- Registration Number
- JPRN-UMIN000009109
- Lead Sponsor
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
- Brief Summary
DOAC administration showed similar post-procedural GI bleeding risk to VKA administration in patients undergoing endoscopic procedures, but it shortened the hospital stay.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 450
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with unstable vital sign with high risk of endoscopy. 2) Patients with apparent GI bleeding before endoscopy. 3)Pregnant, breast-feeding women and possibility of pregnancy 4)Patients who will perform endoscopic biopsy and treatment during the same hospitalization period 5)Patients who were considered not suitable to be included in this study by the physician.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of GI bleeding within one month after the endoscopy or endoscopic treatment
- Secondary Outcome Measures
Name Time Method 1. Duration of hospitalization 2. Prevalence of cardiovascular and cerebro- and systemic vascular events after endoscopy or endoscopic treatment 3. Frequency of requiring re-endoscopy 4. Frequency of massive GI bleeding 5. Frequency of massive GI bleeding threatening life 6. Frequency of cerebrovascular bleeding